As reported in the Journal of Clinical Oncology by Brad S. Kahl, MD, and colleagues, long-term follow-up of the phase III Eastern Cooperative Oncology Group RESORT study (E4402) showed that rituximab maintenance did not improve overall survival vs rituximab retreatment in rituximab induction...
As reported in the Journal of Clinical Oncology by Han et al, the 21-year update of the Normal Risk Ovarian Screening Study (NROSS) has shown that the NROSS screening strategy remains effective for the detection of ovarian cancer and detection at early disease stages. Study Details The NROSS...
As reported in The New England Journal of Medicine by Alexander Drilon, MD, and colleagues, the phase I/II TRIDENT-1 trial showed the activity of the next-generation ROS1 tyrosine kinase inhibitor repotrectinib in patients with ROS1 fusion–positive non–small cell lung cancer (NSCLC) with no...
In an Indian single-institution study reported in JCO Global Oncology, Patel et al found that use of lower-than-recommended doses of immune checkpoint inhibitors showed activity across various tumor types. As stated by the investigators: “The cost of immune checkpoint inhibitors limits their...
In an analysis from the phase III GALLIUM study reported in the Journal of Clinical Oncology, Pott et al identified measurable residual disease (MRD) status and related outcomes among patients receiving obinutuzumab- and rituximab-based treatment for previously untreated follicular lymphoma. Study...
In a retrospective analysis reported in JAMA Oncology, Bolze et al identified a group of women at low risk for breast cancer based on genetic analysis. The findings may support altering cancer screening in this low-risk group. As stated by the investigators, “Genetic information is not being used...
Editor’s note: On publication of this news item reporting on a paper by Dr. Cullen Taniguchi and colleagues, The ASCO Post learned of Dr. Taniguchi’s untimely death on November 14, 2023. To read about the remarkable life and career of Dr. Taniguchi, please visit gsbs.uth.edu. In a phase Ib/II trial ...
In a long-term analysis from the LYMA trial reported in the Journal of Clinical Oncology, Sarkozy et al found that rituximab maintenance following autologous stem cell transplantation (ASCT) continued to be of benefit vs observation in the first-line treatment of younger patients with mantle cell...
In the Chinese phase II NACI trial reported in The Lancet Oncology, Li et al found that neoadjuvant chemotherapy plus camrelizumab produced antitumor activity and had a manageable adverse event profile in patients with locally advanced cervical cancer. Study Details A total of 85 patients were...
In an analysis reported in JAMA Oncology, Kerekes et al found that initiation of immunotherapy at the end of life has increased over time in U.S. patients with metastatic cancers. Study Details The retrospective cohort study used data from the National Cancer Database on patients with stage IV...
In the European CAMINO study reported in The Lancet Oncology, Görgec et al identified the likelihood of change in treatment plans with the addition of contrast-enhanced magnetic resonance imaging (MRI) in patients scheduled for local therapy for colorectal liver metastases on the basis of...
As reported in the Journal of Clinical Oncology by Timmins et al, a pooled analysis of 19 international cohorts showed that high vs low self-reported leisure-time physical activity was associated with a reduced risk of premenopausal breast cancer. Study Details The study used individual-level data ...
In a Dutch nationwide cross-sectional cohort study reported in JAMA Oncology, Hazen et al found that a reduced use of neoadjuvant radiotherapy as part of chemoradiotherapy was not associated with poorer outcomes in patients with non–locally advanced rectal cancer. As stated by the investigators,...
As reported in the Journal of Clinical Oncology by Foà et al, long-term results of the Italian D-ALBA study have shown that a chemotherapy-free induction/consolidation regimen of dasatinib followed by blinatumomab maintained highly favorable outcomes in the front-line treatment of adult patients...
As reported in The Lancet Oncology by Pfister et al, a 5-year analysis of the French phase III VESPER trial showed no improvement in overall survival with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) vs gemcitabine and cisplatin (GC) in the total perioperative...
In the phase II CURB trial reported in The Lancet, Chiaojung Jillian Tsai, MD, PhD, and colleagues found that the addition of stereotactic body radiotherapy (SBRT) to standard-of-care systemic therapy was associated with improved progression-free survival in the total study population of patients...
As reported in The Lancet Oncology by Kohei Shitara, MD, and colleagues, interim analyses of the phase III KEYNOTE-585 trial have shown that the addition of perioperative pembrolizumab to chemotherapy improved pathologic complete response, but did not significantly improve event-free survival, in...
In an analysis from the IBIS-II prevention trial reported in The Lancet Oncology, Jack Cuzick, PhD, and colleagues found that increasing the ratio of baseline estradiol level to sex hormone–binding globulin (SHBG) was associated with an increased risk of breast cancer in high-risk postmenopausal...
The final survival analysis of the Dutch-Belgian phase III OVHIPEC-1 trial showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery was associated with maintained progression-free and overall survival benefits at 10 years in women with advanced ...
In a final overall survival analysis of the phase III IMvigor130 trial reported in The Lancet Oncology, Enrique Grande, MD, and colleagues found no significant advantage in overall survival with atezolizumab plus chemotherapy vs chemotherapy alone in the first-line treatment of patients with...
As reported in The New England Journal of Medicine by Talha Munir, MBBS, and colleagues, an analysis from the UK phase III FLAIR trial showed improved progression-free survival with measurable residual disease (MRD)-guided ibrutinib/venetoclax vs fludarabine/cyclophosphamide/rituximab (FCR) in...
As reported in The Lancet by Ana Oaknin, MD, and colleagues, the phase III BEATcc trial has shown that the addition of atezolizumab to bevacizumab and chemotherapy improved progression-free and overall survival in women with metastatic, persistent, or recurrent cervical cancer. Study Details The...
In a Danish population-based retrospective cohort study reported in The Lancet Oncology, Kjaer et al identified the cumulative incidence of second primary cancers among cancer survivors aged ≥ 40 years who were alive 1 year after diagnosis. Study Details The study involved data from 457,334...
In the final overall survival analysis from the phase III IMvigor130 trial reported in The Lancet Oncology, Aristotelis Bamias, MD, and colleagues found no significant advantage in overall survival with atezolizumab monotherapy vs chemotherapy in untreated patients with locally advanced or...
On October 16, 2023, pembrolizumab was approved for use with platinum-containing chemotherapy as neoadjuvant treatment and as single-agent adjuvant treatment in patients with resectable (tumors ≥ 4 cm or node-positive) non–small cell lung cancer (NSCLC).1 Supporting Efficacy Data Approval was based ...
As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, overall survival results from the Australian phase II TheraP trial showed no difference with lutetium-177–labeled PSMA-617 (LuPSMA) vs cabazitaxel in patients with metastatic castration-resistant prostate cancer and...
In a subgroup analysis from the phase III FLAURA2 trial reported in the Journal of Clinical Oncology, Pasi A. Jänne, MD, PhD, and colleagues found the combination of osimertinib and chemotherapy improved central nervous system (CNS) efficacy vs osimertinib alone in the first-line treatment of...
As reported in The Lancet by Uwe Platzbecker, MD, and colleagues, the phase III IMerge trial has shown improved red blood cell transfusion independence with imetelstat, a competitive telomerase inhibitor, vs placebo in RBC transfusion-dependent patients with lower-risk myelodysplastic syndromes who ...
In a study reported in the Journal of Clinical Oncology, Dixon et al found that adult survivors of childhood cancers with prediabetes were at an increased risk of developing cardiovascular events and chronic kidney disease. The study involved data from 3,529 ≥ 5-year survivors of childhood cancer...
As reported in the Journal of Clinical Oncology by Reshma Jagsi, MD, DPhil, and colleagues, a 5-year analysis of the IDEA trial showed a very low rate of recurrence with the omission of radiotherapy after breast-conserving surgery in patients at low clinical and genomic risk for disease ...
As reported in the Journal of Clinical Oncology by Tan et al, the phase III CANOPY-1 trial has shown no survival benefits with the addition of canakinumab to first-line pembrolizumab plus chemotherapy in patients with advanced/metastatic non–small cell lung cancer (NSCLC) without EGFR or ALK...
As reported in The New England Journal of Medicine by Kathleen N. Moore, MD, and colleagues, the phase III MIRASOL trial has shown improved progression-free and overall survival with mirvetuximab soravtansine-gynx vs chemotherapy in previously treated patients with folate receptor–alpha...
As reported in the Journal of Clinical Oncology by Innocenti et al, analysis of DNA mutational profiling in the phase III CALGB (Alliance)/SWOG 80405 trial of patients with metastatic colorectal cancer treated with bevacizumab or cetuximab with chemotherapy showed differences in outcome associated...
In a study reported in the Journal of Clinical Oncology, Han et al found that persistent human papillomavirus (HPV) circulating tumor DNA (ctDNA) after chemoradiation was associated with poorer outcomes in patients with cervical cancer. Patients at high risk of poorer outcomes could also be...
In a systematic review and meta-analysis reported in The Lancet Oncology, Fujiwara et al found that the addition of immune checkpoint inhibitors to perioperative therapy in patients with solid tumors was associated with an increased risk of grade 3 and 4 treatment-related adverse events and adverse ...
On October 11, 2023, the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) was approved for patients with metastatic non–small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA...
A large cohort study of peripheral blood T-cell receptor (TCR) clonotype diversity in patients with breast cancer diagnosed with either ductal carcinoma in situ or de novo stage IV disease has found that the diversity of T cells is associated with age and intratumor immune status and might be...
In an analysis from the European Mantle Cell Lymphoma Elderly Trial reported in the Journal of Clinical Oncology, Hoster et al found that outcomes with rituximab maintenance were better in patients aged ≥ 60 years with mantle cell lymphoma who had measurable residual disease (MRD)-negative vs...
As reported in The New England Journal of Medicine by Yohann Loriot, MD, PhD, and colleagues, cohort 1 of the phase III THOR trial has shown improved overall survival with erdafitinib vs chemotherapy in patients with locally advanced, unresectable, or metastatic urothelial carcinoma with...
As reported in The Lancet Oncology by Bradley J. Monk, MD, and colleagues, the phase III CALLA trial showed no significant improvement in progression-free survival with the addition of durvalumab to chemoradiotherapy in previously untreated patients with locally advanced cervical cancer. Study...
As reported in The Lancet Oncology by Josep M. Llovet, MD, and colleagues, the phase III LEAP-002 trial has shown that the addition of pembrolizumab to lenvatinib in the first-line treatment of unresectable hepatocellular carcinoma did not reach statistical superiority thresholds for overall or...
In the phase II PNOC001 trial reported in the Journal of Clinical Oncology, Daphne A. Haas-Kogan, MD, MBA, and colleagues found that everolimus showed activity in pediatric patients with recurrent or progressive low-grade glioma. PI3K/AKT/mTOR pathway activation was not correlated with clinical...
In a combined analysis of two Chinese phase II trials (RC48-C005 and RC48-C009) reported in the Journal of Clinical Oncology, Sheng et al found that the antibody-drug conjugate disitamab vedotin—an anti-HER2 antibody conjugated with monomethyl auristatin—produced promising results in patients with...
As reported in the Journal of Clinical Oncology by Charles M. Rudin, MD, PhD, and colleagues, the phase III SKYSCRAPER-02 trial showed no progression-free or overall survival benefit with the addition of the T-cell immunoglobulin and ITM domain (TIGIT) inhibitor tiragolumab to atezolizumab and...
As reported in The Lancet Oncology, Im et al have developed risk-prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer. Study Details In the study, models to predict age-specific risk of primary ovarian insufficiency were evaluated among 5-year survivors...
In a nationwide Danish cohort study reported in JAMA Oncology, Nors et al found the 5-year risk of recurrence after surgery for stage I to III colorectal cancer decreased over time and the time to recurrence was shorter with a more advanced disease stage. Study Details The study used the Danish...
In the phase II SPRINT trial reported in the Journal of Clinical Oncology, Ohri et al found that a chemotherapy-sparing regimen of pembrolizumab with risk-adapted radiotherapy was associated with good outcomes in patients with stage III or unresectable stage II non–small cell lung cancer (NSCLC)...
In a European study reported in the Journal of Clinical Oncology, Heymer et al found that the risk of subsequent colorectal cancer was elevated among childhood cancer survivors who had undergone abdominopelvic radiotherapy. Study Details The study used data from the PanCareSurFup Study—a...
In a German phase II trial (INITIAL-1) reported in the Journal of Clinical Oncology, Matthias Stelljes, MD, and colleagues found that inotuzumab ozogamicin–based induction therapy followed by age-adapted chemotherapy was associated with promising outcomes in newly diagnosed patients older than age...
In an Indian phase II trial reported in the Journal of Clinical Oncology, Ostwal et al found that trastuzumab plus gemcitabine/cisplatin was active in treatment-naive patients with advanced HER2-positive biliary tract adenocarcinoma. Study Details In the investigator-initiated multicenter trial, 90 ...